Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KAZIA THERAPEUTICS LTDKZIA · Entity 6537 | Director | January 08, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KAZIA THERAPEUTICS LTD
Report date January 08, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 | Direct | 75,000 |
Reported balance
After 2026-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 75,000 · Balance 75,000 F1: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANTARES PHARMA, INC.
Report date May 24, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-24 · Disposition to issuer · Disposed 1,876,693 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-24 · Disposition to issuer · Disposed 611,667 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-05-24 · Disposition to issuer · Disposed 374,099 · Balance 0 F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-24 · Disposition to issuer · Disposed 21,658 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-24 · Disposition to issuer · Disposed 56,300 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-24 · Disposition to issuer · Disposed 288,786 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-24 · Disposition to issuer · Disposed 773,700 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.66 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-24 · Disposition to issuer · Disposed 725,751 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-24 · Disposition to issuer · Disposed 591,510 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-24 · Disposition to issuer · Disposed 567,423 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-24 · Disposition to issuer · Disposed 776,617 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-05-24 · Disposition to issuer · Disposed 474,629 · Balance 0 F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
F4: Each Company performance restricted stock unit ("Company PSU") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
F5: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2017 Filed Apr 5, 2017 17:26 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | SaleCommon Stock | 37,000 | $3.00 | $111,070.30 |
DisclosureSEC source: 0001209191-17-025766 · doc4.xml · nonDerivative · entry 2 APPLE ROBERT F · CIK 0001054942 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,002 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock option reported on this Form 4 was due to expire on May 10, 2017. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 17:26 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Exercise / conversionCommon Stock | 37,000 | $1.65 | $61,050.00 |
DisclosureSEC source: 0001209191-17-025766 · doc4.xml · nonDerivative · entry 1 APPLE ROBERT F · CIK 0001054942 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock option reported on this Form 4 was due to expire on May 10, 2017. Read SEC document |
| February 22, 2017 Filed Jun 9, 2017 16:33 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Tax withholdingCommon Stock | 1,763 | $2.37 | $4,178.31 |
DisclosureSEC source: 0001209191-17-038901 · doc4.xml · nonDerivative · entry 2 APPLE ROBERT F · CIK 0001054942 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,849 F1 · kind: On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| February 22, 2017 Filed Jun 9, 2017 16:33 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 5,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038901 · doc4.xml · nonDerivative · entry 1 APPLE ROBERT F · CIK 0001054942 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,612 F1 · kind: On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:33 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-16-157033 · doc4.xml · derivative · entry 3 APPLE ROBERT F · CIK 0001054942 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2017-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested in equal quarterly installments over three years following the grant date of January 16, 2007. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.